SCHEMBL30429291

SCHEMBL30429291

Cc1cc(O)c(N)cc1C(c1cc(N)c(O)cc1C)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.36
ALOX15 P16050 5/20 0.36
HSD17B10 Q99714 4/20 0.36
GAA P10253 7/20 0.36
MAPT P10636 5/20 0.36
PKM P14618 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
ALOX12 P18054 2/20 0.33
HIF1A Q16665 2/20 0.33
RECQL P46063 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 3/20 0.32
LMNA P02545 2/20 0.32
TSHR P16473 1/20 0.32
CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24191002 1.00 ALDH1A1 (0.36) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL31694457 0.82 ALOX15 (0.44) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL22326131 0.82 ALOX15 (0.44) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL22326112 0.80 CYP3A4 (0.46) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL24191375 0.79 GAA (0.40) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL24191379 0.78 ADRA2A (0.41) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL24191377 0.77 ALOX15 (0.38) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL22336948 0.74 ESR1 (0.31) TSHRESR1ESR2CYP3A4MAPK1
SCHEMBL25207189 0.74 SMN1; SMN2 (0.50) ALDH1A1ALOX15HSD17B10GAAMAPT
SCHEMBL24191371 0.74 HMGCR (0.34) ALDH1A1ALOX15HSD17B10GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303480-A1 Polybenzoxazole, Polyamide, Polyamide Solution, Insulating Material for High-Frequency Electronic Component, High-Frequency Electronic Component, High-Frequency Equipment, Insulating Material for Producing High-Frequency Electronic Component, Method for Producing Polyamide, Method for Producing Polybenzoxazole, Method for Producing Insulating Material for High-Frequency Electronic Component, and Diamine or Salt Thereof CENTRAL GLASS COMPANY, LIMITED (JP) 2023-09-28 US disclosed
EP-4194482-A1 POLYBENZOXAZOLE, POLYAMIDE, POLYAMIDE SOLUTION, INSULATION FOR HIGH-FREQUENCY ELECTRONIC COMPONENT, HIGH-FREQUENCY ELECTRONIC COMPONENT, HIGH-FREQUENCY EQUIPMENT, INSULATION MATERIAL FOR PRODUCING HIGH-FREQUENCY ELECTRONIC COMPONENT, METHOD FOR PRODUCING POLYAMIDE, METHOD FOR PRODUCING POLYBENZOXAZOLE, METHOD FOR PRODUCING INSULATION FOR HIGH-FREQUENCY ELECTRONIC COMPONENT, AND DIAMINE OR SALT THEREOF Central Glass Company, Limited (JP) 2023-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303480-A1 Polybenzoxazole, Polyamide, Polyamide Solution, Insulating Material for High-Frequency Electronic Component, High-Frequency Electronic Component, High-Frequency Equipment, Insulating Material for Producing High-Frequency Electronic Component, Method for Producing Polyamide, Method for Producing Polybenzoxazole, Method for Producing Insulating Material for High-Frequency Electronic Component, and Diamine or Salt Thereof PUF60, TET1, PBRM1 ALDH1A1 2031/4885ALOX15 4223/4885HSD17B10 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.